Nathaniel Washburn,Inessa Schwab,Daniel Ortiz,Naveen Bhatnagar,Jonathan C. Lansing,Amy Medeiros,Steven Tyler,Divya Mekala,Edward Cochran,Hetal Sarvaiya,Kevin Garofalo,Robin Meccariello,James W. Meador,Laura Rutitzky,Birgit C. Schultes,Leona Ling,William Avery,Falk Nimmerjahn,Anthony M. Manning,Ganesh V. Kaundinya,Carlos J. Bosques

Abstract:Significance IgG fragment crystallizable domain (Fc) sialylation has emerged as an important but controversial concept for regulating anti-inflammatory activity of antibodies. Moreover, translating this concept to potent anti-inflammatory therapeutics has been hampered by the difficulty of generating suitable sialylated products for human use. We describe for the first time, to our knowledge, the development of a robust, scalable process to generate a sialylated intravenous immunoglobulin (IVIg) drug candidate with maximum Fc sialylation devoid of unwanted modifications. By using a wide panel of physicochemical analytics and in vivo models, we have validated the quality and potent anti-inflammatory activity of this clinical candidate. This report not only confirms the controversial anti-inflammatory activity of IgG-Fc sialylation, it also represents the first sialylated IVIg preparation, to our knowledge, with consistent anti-inflammatory potency suitable for clinical development.

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity